TUNAR (pTUNAR / BNLN) review notes

UniProt A0A1B0GTB2 (TUNAR_HUMAN), 48 aa, Swiss-Prot reviewed. HGNC:44088 "TCL1 upstream
neural differentiation-associated RNA". The locus was long annotated as a lncRNA (TUNA,
HI-LNC78, LINC00617; zebrafish megamind). Mouse ortholog A0A1B0GQX2.

Literature found (PubMed esearch "TUNAR micropeptide", "Tunar microprotein", "BNLN micropeptide")

Only two primary papers characterise the peptide:

  1. PMID:34513312 Li et al. 2021 Mol Ther Nucleic Acids (full text cached). Human islets / rat INS-1 /
    mouse and human islets. Names the peptide BNLN.
  2. PMID:35036403 Senis et al. 2021 Front Cell Dev Biol (full text cached, fetched this session).
    Mouse ESCs, N2A, cortical neurons, in utero electroporation. Names it pTUNAR. This is the
    paper behind the UniProt "By similarity" (A0A1B0GQX2) statements and the ISS rows.

Other TUNAR papers (e.g. PMID:33682459 TUNAR lncRNA and Wnt signalling in beta cells;
PMID:29540255 glioma paper, WITHDRAWN) treat TUNAR as an RNA and are not relevant to the
protein's GO annotation.

Key findings

Coding / structure

Localization

SERCA interaction - direction of effect is DISCORDANT

Conclusion: evidence supports SERCA binding (two isoforms, two labs, co-IP + PLA) and an effect
on ER/cytosolic Ca2+, but not a direction-specific MF (activator vs inhibitor). Unlike DWORF
(STRIT1: GO:0141109 transporter activator activity) and ERLN (GO:0042030 ATPase inhibitor
activity), there is no purified-system or pump-kinetics measurement. I therefore keep ATPase
binding (GO:0051117) as the core MF and do NOT propose GO:0042030/GO:0141109 or
GO:1901895/GO:1901896. GO:1901894 (direction-neutral regulation of ATPase-coupled calcium
transmembrane transporter activity) is plausible but also not directly measured; raised as a
question rather than NEW.

Downstream physiology

Annotation decisions (summary)